Andrea Park's questions to BioMarin Pharmaceutical Inc (BMRN) leadership • Q2 2025
Question
Andrea Park, on behalf of Joseph Schwartz at Leerink Partners, questioned how predictive VOXZOGO's current low discontinuation rates are and how these rates might change with the introduction of competitors.
Answer
Cristin Hubbard, EVP and Chief Commercial Officer, stated that the vast majority of children on VOXZOGO adhere to daily dosing, supported by robust patient support programs, which is a core strength for BioMarin. She emphasized the company's focus on finding, starting, and keeping patients on therapy to ensure the best long-term outcomes, a strategy that will continue regardless of the competitive landscape.